Published in Cancer Weekly, January 29th, 2002
The innovative new EIAs will be based on the same gold standard antibodies utilized in the Fujirebio Diagnostics Radioimmunoassays (RIA). The assays will be available in Southeast Asia in Q1 2002 and later launched in Latin America, the Middle East, and Eastern Europe. The assays were codeveloped with Trinity Biotech , an international medical diagnostics company.
The new EIAs will target ovarian...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.